Braze, Inc. (BRZE) closed the last trading session at $34.93, gaining 23.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $46.63 indicates a 33.5% upside potential.The average comprises 19 short-term price targets ranging from a low of $38.00 to a high of $68.00, with a standard deviation of $6.53. While the lowest estimate indicates an increase of 8.8% from the current price lev ...

Core Viewpoint - nCino (NCNO) shows potential for significant upside, with a mean price target of $34.8 indicating a 34.3% increase from the current price of $25.92 [1] Price Targets and Analyst Estimates - The mean estimate consists of 15 short-term price targets with a standard deviation of $4.02, suggesting variability in analyst predictions [2] - The lowest estimate is $27.00, indicating a 4.2% increase, while the highest estimate is $41.00, suggesting a potential surge of 58.2% [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about nCino's earnings prospects, with a strong consensus on higher EPS estimates [11] - Over the last 30 days, five estimates have been revised upward, leading to a 55.1% increase in the Zacks Consensus Estimate [12] - nCino holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While consensus price targets may not be reliable indicators of the extent of potential gains, they can provide a directional guide for price movement [14]

Loar Holdings Inc. (LOAR) closed the last trading session at $71.37, gaining 4.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $92.5 indicates a 29.6% upside potential.The average comprises four short-term price targets ranging from a low of $90.00 to a high of $97.00, with a standard deviation of $3.11. While the lowest estimate indicates an increase of 26.1% from the current p ...

BioVie Inc. (BIVI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing ...

Core Viewpoint - Altimmune, Inc. (ALT) has shown a significant price increase of 28.4% over the past four weeks, with a mean price target of $17.88 indicating a potential upside of 229.3% from the current price of $5.43 [1] Price Targets and Analyst Consensus - The average price target for ALT includes eight short-term estimates ranging from a low of $1.00 to a high of $28.00, with a standard deviation of $8.81, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 81.6%, while the highest points to an upside of 415.7% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price direction, which can be a useful starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ALT's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.8%, with one estimate moving higher and no negative revisions [12] - ALT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] - Investors should approach price targets with skepticism and consider them as one of many factors in their decision-making process [10]

Core Viewpoint - Evolv Technologies Holdings, Inc. (EVLV) shares have seen a 0.7% increase over the past four weeks, closing at $6.77, with a potential upside of 45.9% based on Wall Street analysts' mean price target of $9.88 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.25, indicating a consensus among analysts. The lowest estimate of $9.50 suggests a 40.3% increase, while the highest target of $10.00 indicates a 47.7% increase [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about EVLV's earnings prospects, as indicated by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 15% over the past month, with no negative revisions [11][12] - EVLV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, it should not be the sole basis for investment decisions due to the questionable reliability of analysts in setting these targets [3][10] - Analysts may set overly optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Core Viewpoint - Byrna Technologies Inc. (BYRN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Byrna Technologies' Earnings Outlook - Byrna Technologies is projected to earn $0.40 per share for the fiscal year ending November 2025, with no year-over-year change expected [8]. - Over the past three months, the Zacks Consensus Estimate for Byrna Technologies has increased by 6.1%, reflecting a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade of Byrna Technologies to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Rentokil Initial PLC (RTO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance Indicators - Rentokil Initial is projected to earn $1.28 per share for the fiscal year ending December 2025, with no year-over-year change expected [8]. - Over the past three months, the Zacks Consensus Estimate for Rentokil Initial has increased by 0.3%, reflecting a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimates into five groups, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - The upgrade of Rentokil Initial to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Howmet (HWM) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade for Howmet reflects an improvement in the company's underlying business, suggesting that investor sentiment regarding this trend could drive the stock price higher [4]. - For the fiscal year ending December 2025, Howmet is expected to earn $3.69 per share, with a 2.9% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [6]. - The upgrade of Howmet to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [9].

Investors might want to bet on Staar Surgical (STAA) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earni ...